Sierra Oncology Announces Submission of New Drug Application for Momelotinib to US Food & Drug Administration
– Submission seeks approval of momelotinib for the treatment of myelofibrosis – SAN MATEO, Calif.–(BUSINESS WIRE)–Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for momelotinib, … [Read more…]